CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an Envelope addressed to: Mail Stop Disclosure Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:)

Stefan Schorling Unassigned) Examiner:

SERIAL NO.: 10/587,386) ART UNIT: Unassigned

INTERNATIONAL FILING DATE: FEBRUARY, 8, 2005) Confirmation No. N/A

) DOCKET NO: 22398-US

NEW PRIMERS AND PROBES FOR

THE DETECTION OF PARVOVIRUS

B19

INFORMATION DISCLOSURE STATEMENT

Mail Stop Disclosure. Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56, 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits, whichever event occurs last. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,

Date:

Correspondence Address:

Roche Molecular Systems, Inc 1145 Atlantic Avenue Alameda, CA 94501

Tele: (510) 814-2800 Fax: (510) 814-2973

U.S. Department of Commerce Patent and Trademark Office LIST OF INFORMATION CITED BY APPLICANT (Use several sheets if necessary)				Atty. Docket No. 22398-US Serial No. 10/587.386 Applicant: Stefan Schorling						
				International Filing Date: February 5, 2005 Group: N/A						
321 00 2000	الغ		IIS PA'	TENT I	DOCUMENTS			-		
TO MAN DE	<i>\$/</i>	DOCUMENT NUMBER	ISSUE		NAME	CLASS	SUBCLASS	FILIN	G DATE	
INFIAL	1	4,458,066	07/03	3/84	Caruthers, et al.	536	27	03/2	24/81	
	2	4,996,143	02/26	5/91	Heller, et al.	435	6	04/	13/90	
	3	5,130,238	07/14	1/92	Malek. et al.	435	91	08/23/89		
	4	5,210,015	05/11	1/93	Gelfand, et al.	435	6	08/06/90		
	5	5,386,024	01/31	/95	Kacian, et al.	536	25.4	02/10/93		
	6	5,478,972	12/26	5/95	Mizutani, et al.	174	250	08/25/94		
	7	5,487,972	01/30)/96	Gelfand, et al.	435	6	01/05/93		
	8	5,565,322	10/15	5/96	Heller, M	435	6	11/6/92		
	9	5,585,254	12/17	7/96	Maxwell, et al.	435	172.3	04/02/93		
	10	5,804,375	09/08	3/98	Gelfand, et al.	435	6	04/25/95		
	11	5,849,489	12/15	5/98	Heller, M	435	6	08/23/96		
	12	6,103,476	08/15	5/00	Tyagi, et al.	435	6	03/15/99		
	13	6,162,603	12/19	9/00	Heller, M	435	6	07/28/98		
	14	6,174,670 B1	01/16	5/01	Wittwer, et al.	435	. 6	06/	04/97	
	15	6,183,999 B1	02/06	5/01	Weimer, et al.	435	91.2	11/	24/98	
	16	6,268,349 B1	07/31	1/01	Hirschman, S	514	44	04/15/97		
	17	6,274,307 B1	08/14	1/01	Soutschek, et al.	435	5	05/15/97		
	18	6,395,472 B1	05/28	3/02	Leary, et al.	435	5	02/05/99		
	-	. E	DEICN	DATEN	T DOCUMENTS				-	
· I		DOCUMENT NUMBER	PUBLICA		COUNTRY	CLASS	SUBCLASS	TRANS	RANSLATION	
			DA	TE				YES	NO	
	19	PCT/EP2005/001243 Search Report	05/31	1/05	PCT					
	20	37 24442 A1	02/02	2/89	DE					
	21	37 34442 A1	04/27	7/89	DE					
	22	0 238 893 B1	03/02	2/87	EP					
	23	0 439 182 B1	01/25	5/91	EP				1	
	24	04 - 88985	03/23	3/92	JР				X	
	25	11 - 221099	08/17	7/99	JР				Х	
	26	WO 90/01069	02/08	3/90	PCT	<u> </u>		 	<u> </u>	

			,				
27	WO 91/04330	04/04/91	PCT				
28	WO 91/12079	08/22/91	PCT				T
25	WO 92/02208	05/29/92	PCT				+
36	WO 96/09391	03/28/96	PCT				†
31	WO 96/41811	12/27/96	PCT				
32	WO 98/04730	02/05/98	PCT				
33	WO 99/16781	04/08/99	PCT				
34	WO 99/28439	06/10/99	PCT				-
35	WO 00/24917	05/04/00	PCT				
36	WO 01/06019 A2	01/25/01	PCT				_
37	WO 01/14593 A2	03/01/01	PCT				-
38		05/25/01	PCT				ļ
39		01/0302	PCT				-
40	77.00721712						
		01/09/03	PCT				
41		08/18/05	PCT				
42	2 146 372 C1	10/03/00	RU				
	OTHED ART ([ncluding Author,]	Citle Dete Portin	ont Dages E	(ta.)		
4.						l Biotechr	101001
	Abramson, R., et al., 1993, "Nucleic acid amplification technologies", Analytical E				Dioicein	orogy	
44	Alderton, R., et al., 1992, "Magnetic Bead Purification of M13 DNA Sequencing Templates",						
	Analytical Biotechnology, 201:166-169						
4:							
	Infectiosum (Fifth Disease)?", The Lancet, June 18, 1983, p. 1378						
40	Astell, C., et al., 1987, "Structural and Functional Homology of Parvovirus and Papovavirus						
			unctional Florito	logy of full	ovii us uitu	Tapova	vii us
4:	Polypeptides", J.gen.Virol., 68: 885-893 Aubin, J., et al., 2000, "Large-Scale Screening for Human Parvovirus B19 DNA y PCR:						
						•	
48		Application to the Quality Control of Plasma for Fractionation", Vox Sang, 78:7-12					11
	Ausubei, r., et al., 20	Ausubel, F., et al., 2000, "Current Protocols in Molecular Biology", Supplement 55, 1:1-11					
49	Barany, F., 1991, "Th	e Ligase Chain Re	action in a PCR V	World", PCR	Methods an	ıd Applica	ıtions
50	Barany, F., 1991, "Genetic disease detection and DNA amplification using cloned						
	thermostable ligase", Proc. Natl. Acad Sci, 88:189-193						
5.	Beaucage, S., et al., 1981, "Deoxynucleoside Phosphoramidites - A New Class of Key						
	Intermediates for Deoxypolynucleotide Synthesis", Tetrahedron Letters, 22(20):1859-1862						
52							
52	Boom, R., et al., 1990,	"Rapid and Simp	le Method for Pu	rification of	f Nucleic A	cids", Jou	ırnai

Clinical Microbiology, 28(3):495-503

Page 3 of 5

. 5	blown, L., et al., 1777, Chemical Synthesis and Clothing of a Tyrosine ixiva Gene Wethous in
	Enzymology, 68 (<u>8</u>):109-151
5	Brown, K., 2000, "Haematological Consequences of Parvovirus B19 Infection", Bailliere's Clinical Haematology, 13(2):245-259
5	<u> </u>
5	Cohen, B., 1995, "Parvovirus B19: an expanding spectrum of disease", BMJ, 311:1549-1552
5	Cotmore, S., et al., 1986, "Identification of the major Structural and nonstructural Proteins Encoded by Human Parvovirus B19 and mapping of Their genes by Procaryotic Expression of Isolated Genomic Fragments", Journal of Virology, 60(2):548-557
5	
5	Dorsch, S., et al., 2001, "The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability", <i>Journal of General Virology</i> , 82: 191-199
6	Düx, S., et al., 2002, "Parvovirus B19 Myocarditis in a young man with Previous non-bacterial meningitis", Dtsch Med Wochenschr, 127:1584-1588
6	Enders, G., et al., 1998, "Life-Threatening Parvovirus B19-Associated Myocarditis and Cardiac Transplantation as Possible Therapy: Two Case Reports", Clinical Infectious Diseases, 26;355-358
6	Enders, G., "Viral Infections of the Fetus Neonate, other than Rubella", Topley & Wilson's Microbiology and Microbial Infections, 9th Ed., by Collier, L., et al., Arnold Publishers 1998, pp 873-915
6	
6	
6	
. 6	
6	Harder, T., et al., 2001, "New LightCycler PCR for Rapid and Sensitive Quantification of Parvovirus B19 DNA Guides Therapeutic Decision-Making in Relapsing Infections", Journal of Clinical Microbiology, 39(12): 4413-4419
6	Hemauer, A., 1996, "Sequence variability among different parvovirus B19 isolates", Journal of General Virology" 77:1781-1785
6	
7	
7	
7	

	DNA, Molecular Diagnosis, 1(4):321-328
 73	Junkind, D., 2001, "Automation of laboratory testing for infectious diseases using the
	polymerase chain reaction – our past, our present, our future", Journal of Clinical Virology, 20:1-
	6
74	Kwoh, D., 1989, "Transcription-based amplification system and detection of amplified human
	immunodeficiency virus type 1 with a bead-based sandwich hybridization format", Proc. Natl.
	Acad. Sci. USA, 86:1173-1177
75	Marko, M., 1982, "A Procedure for the Large-Scale Isolation of Highly Purified Plasmid DNA
	Using Alkaline Extraction and Binding to Glass Powder", Analytical Biochemistry, 121:382-387
76	Müller, J., et al., 2002, "Development and Validation of a Real-Time PCR Assay for Routine
	testing of Blood Donations for Parvovirus B19 DNA", Infus Ther Transus Med, 29:254-258
77	Narang, S., et al., 1979, "Improved Phosphotriester Method for the Synthesis of Gene
	Fragments", Methods in Enzymology, 68(6):90-98
78	Nguyen, Q., et al., 2002, "Identification and Characterization of a Second Novel Human
	Erythrovirus Variant, A6", Virology, 301:374-380
79	Ozawa, K., et al., 1988, "Functional Mapping of the Genome of the B19 (Human) Parvovirus
	by In Vitro Translation after Negative Hybrid Selection", Journal of Virology, 62(7):2508-2511
80	Pattison, J., et al., 1981, "Parvovirus Infections and Hypoplastic Crisis in Sickle-Cell
	Anaemia", The Lancet, March 21, 1998, pp 664-665
81	Sambrook, J., et al., 1989, "Molecular Cloning A Laboratory Manual", CSH, 2 nd Edition. Cold
	Spring Harbor Laboratory Press.
82	Sato, K., et al., 2000, "Development of a Hypersensitive Detection Method for Human
	Parvovirus B19 DNA", Journal of Clinical Microbiology, 38(3):1241-1243
83	Schmidt, J., et al., 2001, "Parvovirus B19 DNA in plasma pools and plasma derivatives", Vox
 0.4	Sanguinis, 81: 228-235
84	Schorling, S., et al., 2004, "Quantification of Parvovirus B19 DNA using COBAS AmpliPrep
	Automated Sample Preparation and LightCycler real-Time PCR", Journal of Molecular
85	Diagnostics, 6(1):37-41
83	Servant, A., et al., 2002, "Genetic Diversity within Human Erythroviruses: Identification of
86	Three Genotypes", Journal of Virology, 76(18):9124-9134
"	Shade, R., et al., 1986, "Nucleotide Sequence and Genome Organization of Human Parvovirus
	B19 Isolated from the Serum of a Child during Aplastic Crisis", Journal of Virology, 58(3):921-936
87	Stelzl, E., et al., 2002, "Evaluation of an Automated Sample Preparation Protocol for
	Quantitative Detection of Hepatitis C Virus RNA", <i>Journal of Clinical Microbiology</i> , 40 (<u>4</u>):1447-
	1450
 88	Takahashi, N., et al., 1999, "Genetic heterogeneity of the immunogenic viral capsid protein
	region of human parvovirus B19 isolates obtained from an outbreak in a pediatric ward",
	FEBS Letters, 450 :289-293
 89	Turton, J., et al., 1990, "Similarities in nucleotide sequence between serum and faecal human
	parvovirus DNA", Epidemiol. Infect., 105:197-201
90	Uhlmann, E., et al., 1990, "Antisense Oligonucleotides: A New Therapeutic Principle",
	ChemicalReviews, 90(4):544-584
91	Umene, K., et al., 1995, "A new genome type of human parvovirus B19 present in sera of
	patients with encephalopathy", Journal of General Virology, 76:2645-2651

Attorney Docket: 22398-US International Filing Date: February 5, 2005

Serial No. 10/587,386 Page 5 of 5

	92	Vassias, I., et al., 1993, "An in situ hybridization technique for the study of B19 human				
	1	parvovirus replication in bone marrow cell cultures", Journal of Virological Methods, 44:329-338				
· · · · · · · · · · · · · · · · · · ·	02					
	93	Verma, S., et al., 1998, "Modified Oligonucleotides: Synthesis and Strategy for Users", Annu.				
·		Rev. Biochem, 67:99-134				
	94	Vogelstein, B., et al., 1979, "Preparative and analytical purification of DNA from agarose",				
		Proc. Natl. Acad. Sci. USA, 76(2):615-619				
	95	Walsh, C., "Acyl Transfers to Water: Endopeptidases and Exopeptidasses", Enzymatic				
		Reaction Mechanisms, W.H. Freeman and Company San Francisco, Ch. 3 53-107				
	96	Whelen, A., et al., 1996, "The Role of Nucleic Acid Amplification and Detection in the Clinical				
		Microbiology Laboratory", Annu. Rev. Microbiol., 50:349-373				
	97	Wu, D., et al., 1989, "The Ligation Amplification Reaction (LAR) – Amplification of Specific				
		DNA Sequences Using Sequential Rounds of Template-Dependent Ligation", Genomics, 4:560-				
		569				
	98	Yoto, Y., et al., 1996, "Human parvovirus B19 infection associated with acute hepatitis", The				
		Lancet, 347:868-870				
EXAMINER			DATE CONSIDERED			
*EXAMINER	*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in					
conformance and not considered. Include copy of this form with next communication to applicant.						